论文部分内容阅读
目的观察曼月乐(左炔诺孕酮宫内释放系统)在子宫腺肌病治疗中的临床疗效。方法 52例子宫腺肌病患者,随机分为口服药物组与曼月乐组,各26例。口服药物组患者单纯口服药物治疗,曼月乐组患者则行曼月乐宫内放置,对两组对象治疗后的相关指标进行分析。结果治疗后曼月乐组患者月经量为(30.2±2.6)ml少于口服药物组的(59.4±7.3)ml;子宫体积为(220.2±3.1)cm~3小于口服药物组的(242.1±10.4)cm~3;子宫内膜厚度为(5.1±0.9)mm小于口服药物组的(8.2±1.8)mm,差异有统计学意义(P<0.05)。结论在子宫腺肌病的临床治疗中,宫内放置曼月乐疗效确切,安全性高,患者易于接受,值得临床推广。
Objective To observe the clinical efficacy of Mirena (levonorgestrel-releasing intrauterine system) in the treatment of adenomyosis. Methods Fifty-two patients with adenomyosis were randomly divided into oral drug group and Mirena group, with 26 cases in each. Oral drug group patients with oral medication alone, Mirena group patients were placed Mirena intrauterine placement, the two groups of objects after treatment related indicators were analyzed. Results After treatment, the menstrual flow in Mirena group was (30.2 ± 2.6) ml less than that in oral group (59.4 ± 7.3) ml; the uterine volume was (220.2 ± 3.1) cm ~ 3 less than that in oral group (242.1 ± 10.4 ) cm ~ 3. The thickness of endometrium was (5.1 ± 0.9) mm less than that of the oral drug group (8.2 ± 1.8) mm, the difference was statistically significant (P <0.05). Conclusion In the clinical treatment of adenomyosis, intrauterine placement of Mirena is effective, safe and easy to be accepted by patients. It is worthy of clinical promotion.